A Meta-Analysis of Randomized Clinical Trials of Runzao Zhiyang Capsule in Chronic Urticaria
Chinese herbal medicine has many advantages in the treatment of chronic urticaria (CU). Herein, we evaluated the efficacy and safety of the Runzao Zhiyang (RZZY, Chinese patent herbal medicine capsule) capsule for CU through a meta-analysis of randomized clinical trials (RCTs). This meta-analysis in...
Gespeichert in:
| Veröffentlicht in: | Evidence-based complementary and alternative medicine 2022-09, Vol.2022, p.1-13 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 13 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Evidence-based complementary and alternative medicine |
| container_volume | 2022 |
| creator | Ye, Shengzhen Zhang, Xueer Ling, Guihua Xiao, Xianjun Huang, Dan Chen, Mingling |
| description | Chinese herbal medicine has many advantages in the treatment of chronic urticaria (CU). Herein, we evaluated the efficacy and safety of the Runzao Zhiyang (RZZY, Chinese patent herbal medicine capsule) capsule for CU through a meta-analysis of randomized clinical trials (RCTs). This meta-analysis included 17 RCTs involving 1,760 patients. RZZY capsule combined with conventional drugs showed a better clinical total effective rate (risk ratio (RR) = 1.20, 95% confidence interval (CI) (1.15, 1.24), P |
| doi_str_mv | 10.1155/2022/1904598 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9509263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2717516571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-3b42dbc5e68175ed825fcb1e7ef05f1f0a2478d4ffdcb031d595904af3a6f3213</originalsourceid><addsrcrecordid>eNp9kV9LwzAUxYsoOKdvfoCAL4JWk7Rp2hdhFP_BRJANRISQNsmW0SUzaZXt05u5MdAHn-6F-zuHe--JolMErxAi5BpDjK9RAVNS5HtRD9EUxSnO8_1dT18PoyPvZxDiglLai94H4Em2PB4Y3iy99sAq8MKNsHO9kgKUjTa65g0YOc2bzbQzK27B21QvuZmAki9810igDSinzgYajF0bNEFwHB2ooJIn29qPxne3o_IhHj7fP5aDYVynmLRxUqVYVDWRWY4okSLHRNUVklQqSBRSkOOU5iJVStQVTJAgBQlHcpXwTCUYJf3oZuO76Kq5FLU0reMNWzg9527JLNfs98ToKZvYT1YQWOAsCQbnWwNnPzrpWzbXvpZNw420nWeYojxLE5iTgJ79QWe2c-F7PxQlKCN0vdHlhqqd9d5JtVsGQbbOiq2zYtusAn6xwafaCP6l_6e_ATHplE0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2717516571</pqid></control><display><type>article</type><title>A Meta-Analysis of Randomized Clinical Trials of Runzao Zhiyang Capsule in Chronic Urticaria</title><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Ye, Shengzhen ; Zhang, Xueer ; Ling, Guihua ; Xiao, Xianjun ; Huang, Dan ; Chen, Mingling</creator><contributor>Yang, Shuli ; Shuli Yang</contributor><creatorcontrib>Ye, Shengzhen ; Zhang, Xueer ; Ling, Guihua ; Xiao, Xianjun ; Huang, Dan ; Chen, Mingling ; Yang, Shuli ; Shuli Yang</creatorcontrib><description>Chinese herbal medicine has many advantages in the treatment of chronic urticaria (CU). Herein, we evaluated the efficacy and safety of the Runzao Zhiyang (RZZY, Chinese patent herbal medicine capsule) capsule for CU through a meta-analysis of randomized clinical trials (RCTs). This meta-analysis included 17 RCTs involving 1,760 patients. RZZY capsule combined with conventional drugs showed a better clinical total effective rate (risk ratio (RR) = 1.20, 95% confidence interval (CI) (1.15, 1.24), P<0.00001), significantly reduced the adverse reaction rate [RR = 0.68, 95% CI (0.50, 0.92), P=0.01] and recurrence rate [RR = 0.29, 95% CI (0.18, 0.46), P<0.00001], and improved the life quality of patients (mean difference (MD) = −2.95, 95% CI (−4.32, −1.57), P=0.0001). Meanwhile, the serum Interleukin-4 (IL-4) (MD = −13.83, 95% CI (−23.45, −4.20), P=0.005) and immunoglobulin E (IgE) (MD = −22.99, 95% CI (−31.48, −14.50), P<0.00001) of patients in the intervention group decreased more significantly. In all, the RZZY capsule has potential therapeutic advantages and is relatively safe for CU. However, we are cautious about the conclusion, which needs to be further confirmed by more large samples, multicenter, and high-quality research in the later stage.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2022/1904598</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Bias ; Chi-square test ; Chinese medicine ; Clinical trials ; Cytokines ; Experiments ; Hemp ; Herbal medicine ; Histamine ; Immunoglobulin E ; Immunosuppressive agents ; Interleukin 4 ; Medical research ; Meta-analysis ; Patients ; Quality of life ; Urticaria</subject><ispartof>Evidence-based complementary and alternative medicine, 2022-09, Vol.2022, p.1-13</ispartof><rights>Copyright © 2022 Shengzhen Ye et al.</rights><rights>Copyright © 2022 Shengzhen Ye et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Shengzhen Ye et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-3b42dbc5e68175ed825fcb1e7ef05f1f0a2478d4ffdcb031d595904af3a6f3213</citedby><cites>FETCH-LOGICAL-c425t-3b42dbc5e68175ed825fcb1e7ef05f1f0a2478d4ffdcb031d595904af3a6f3213</cites><orcidid>0000-0002-8879-0857</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509263/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509263/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><contributor>Yang, Shuli</contributor><contributor>Shuli Yang</contributor><creatorcontrib>Ye, Shengzhen</creatorcontrib><creatorcontrib>Zhang, Xueer</creatorcontrib><creatorcontrib>Ling, Guihua</creatorcontrib><creatorcontrib>Xiao, Xianjun</creatorcontrib><creatorcontrib>Huang, Dan</creatorcontrib><creatorcontrib>Chen, Mingling</creatorcontrib><title>A Meta-Analysis of Randomized Clinical Trials of Runzao Zhiyang Capsule in Chronic Urticaria</title><title>Evidence-based complementary and alternative medicine</title><description>Chinese herbal medicine has many advantages in the treatment of chronic urticaria (CU). Herein, we evaluated the efficacy and safety of the Runzao Zhiyang (RZZY, Chinese patent herbal medicine capsule) capsule for CU through a meta-analysis of randomized clinical trials (RCTs). This meta-analysis included 17 RCTs involving 1,760 patients. RZZY capsule combined with conventional drugs showed a better clinical total effective rate (risk ratio (RR) = 1.20, 95% confidence interval (CI) (1.15, 1.24), P<0.00001), significantly reduced the adverse reaction rate [RR = 0.68, 95% CI (0.50, 0.92), P=0.01] and recurrence rate [RR = 0.29, 95% CI (0.18, 0.46), P<0.00001], and improved the life quality of patients (mean difference (MD) = −2.95, 95% CI (−4.32, −1.57), P=0.0001). Meanwhile, the serum Interleukin-4 (IL-4) (MD = −13.83, 95% CI (−23.45, −4.20), P=0.005) and immunoglobulin E (IgE) (MD = −22.99, 95% CI (−31.48, −14.50), P<0.00001) of patients in the intervention group decreased more significantly. In all, the RZZY capsule has potential therapeutic advantages and is relatively safe for CU. However, we are cautious about the conclusion, which needs to be further confirmed by more large samples, multicenter, and high-quality research in the later stage.</description><subject>Bias</subject><subject>Chi-square test</subject><subject>Chinese medicine</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Experiments</subject><subject>Hemp</subject><subject>Herbal medicine</subject><subject>Histamine</subject><subject>Immunoglobulin E</subject><subject>Immunosuppressive agents</subject><subject>Interleukin 4</subject><subject>Medical research</subject><subject>Meta-analysis</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Urticaria</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kV9LwzAUxYsoOKdvfoCAL4JWk7Rp2hdhFP_BRJANRISQNsmW0SUzaZXt05u5MdAHn-6F-zuHe--JolMErxAi5BpDjK9RAVNS5HtRD9EUxSnO8_1dT18PoyPvZxDiglLai94H4Em2PB4Y3iy99sAq8MKNsHO9kgKUjTa65g0YOc2bzbQzK27B21QvuZmAki9810igDSinzgYajF0bNEFwHB2ooJIn29qPxne3o_IhHj7fP5aDYVynmLRxUqVYVDWRWY4okSLHRNUVklQqSBRSkOOU5iJVStQVTJAgBQlHcpXwTCUYJf3oZuO76Kq5FLU0reMNWzg9527JLNfs98ToKZvYT1YQWOAsCQbnWwNnPzrpWzbXvpZNw420nWeYojxLE5iTgJ79QWe2c-F7PxQlKCN0vdHlhqqd9d5JtVsGQbbOiq2zYtusAn6xwafaCP6l_6e_ATHplE0</recordid><startdate>20220917</startdate><enddate>20220917</enddate><creator>Ye, Shengzhen</creator><creator>Zhang, Xueer</creator><creator>Ling, Guihua</creator><creator>Xiao, Xianjun</creator><creator>Huang, Dan</creator><creator>Chen, Mingling</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8879-0857</orcidid></search><sort><creationdate>20220917</creationdate><title>A Meta-Analysis of Randomized Clinical Trials of Runzao Zhiyang Capsule in Chronic Urticaria</title><author>Ye, Shengzhen ; Zhang, Xueer ; Ling, Guihua ; Xiao, Xianjun ; Huang, Dan ; Chen, Mingling</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-3b42dbc5e68175ed825fcb1e7ef05f1f0a2478d4ffdcb031d595904af3a6f3213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bias</topic><topic>Chi-square test</topic><topic>Chinese medicine</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Experiments</topic><topic>Hemp</topic><topic>Herbal medicine</topic><topic>Histamine</topic><topic>Immunoglobulin E</topic><topic>Immunosuppressive agents</topic><topic>Interleukin 4</topic><topic>Medical research</topic><topic>Meta-analysis</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Urticaria</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ye, Shengzhen</creatorcontrib><creatorcontrib>Zhang, Xueer</creatorcontrib><creatorcontrib>Ling, Guihua</creatorcontrib><creatorcontrib>Xiao, Xianjun</creatorcontrib><creatorcontrib>Huang, Dan</creatorcontrib><creatorcontrib>Chen, Mingling</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ye, Shengzhen</au><au>Zhang, Xueer</au><au>Ling, Guihua</au><au>Xiao, Xianjun</au><au>Huang, Dan</au><au>Chen, Mingling</au><au>Yang, Shuli</au><au>Shuli Yang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Meta-Analysis of Randomized Clinical Trials of Runzao Zhiyang Capsule in Chronic Urticaria</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><date>2022-09-17</date><risdate>2022</risdate><volume>2022</volume><spage>1</spage><epage>13</epage><pages>1-13</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Chinese herbal medicine has many advantages in the treatment of chronic urticaria (CU). Herein, we evaluated the efficacy and safety of the Runzao Zhiyang (RZZY, Chinese patent herbal medicine capsule) capsule for CU through a meta-analysis of randomized clinical trials (RCTs). This meta-analysis included 17 RCTs involving 1,760 patients. RZZY capsule combined with conventional drugs showed a better clinical total effective rate (risk ratio (RR) = 1.20, 95% confidence interval (CI) (1.15, 1.24), P<0.00001), significantly reduced the adverse reaction rate [RR = 0.68, 95% CI (0.50, 0.92), P=0.01] and recurrence rate [RR = 0.29, 95% CI (0.18, 0.46), P<0.00001], and improved the life quality of patients (mean difference (MD) = −2.95, 95% CI (−4.32, −1.57), P=0.0001). Meanwhile, the serum Interleukin-4 (IL-4) (MD = −13.83, 95% CI (−23.45, −4.20), P=0.005) and immunoglobulin E (IgE) (MD = −22.99, 95% CI (−31.48, −14.50), P<0.00001) of patients in the intervention group decreased more significantly. In all, the RZZY capsule has potential therapeutic advantages and is relatively safe for CU. However, we are cautious about the conclusion, which needs to be further confirmed by more large samples, multicenter, and high-quality research in the later stage.</abstract><cop>New York</cop><pub>Hindawi</pub><doi>10.1155/2022/1904598</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-8879-0857</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1741-427X |
| ispartof | Evidence-based complementary and alternative medicine, 2022-09, Vol.2022, p.1-13 |
| issn | 1741-427X 1741-4288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9509263 |
| source | Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Bias Chi-square test Chinese medicine Clinical trials Cytokines Experiments Hemp Herbal medicine Histamine Immunoglobulin E Immunosuppressive agents Interleukin 4 Medical research Meta-analysis Patients Quality of life Urticaria |
| title | A Meta-Analysis of Randomized Clinical Trials of Runzao Zhiyang Capsule in Chronic Urticaria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T01%3A02%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Meta-Analysis%20of%20Randomized%20Clinical%20Trials%20of%20Runzao%20Zhiyang%20Capsule%20in%20Chronic%20Urticaria&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Ye,%20Shengzhen&rft.date=2022-09-17&rft.volume=2022&rft.spage=1&rft.epage=13&rft.pages=1-13&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2022/1904598&rft_dat=%3Cproquest_pubme%3E2717516571%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2717516571&rft_id=info:pmid/&rfr_iscdi=true |